title: Temporal trends in the use of high-dose potent statins following acute coronary syndrome in Israel.
abstract: OBJECTIVE
  This study aimed to evaluate factors associated with the prescription of high-dose potent statin (HDPS) therapy following hospitalization for acute coronary events.
  
  
  METHODS
  Sub-analysis was made using the data of 3,525 patients enrolled in the 2008 and 2010 Acute Coronary Syndrome Israeli Surveys (ACSIS).
  
  
  METHODS
  Analyses were carried out to identify demographic and clinical factors associated with the prescription of HDPS therapy (atorvastatin 40-80 mg/day or rosuvastatin 20-40 mg/day) at discharge compared with the prescription of lower-dose statins.
  
  
  RESULTS
  Among the study patients, 1,387 (39%) were discharged on HDPS, 1,860 (53%) with lower-dose statin regimens and 278 (8%) with no recommendation for statin therapy. Multivariate logistic regression analysis showed that pre-admission usage of HDPS and participation in the more recent (2010) ACSIS survey were independently associated with a higher likelihood of HDPS prescription at discharge from the index event (odds ratio, OR, 21.07, p < 0.001, and 5.61, p < 0.001, respectively), whereas factors independently associated with a lack of HDPS prescription included age >75 years (OR 0.76, p = 0.03), low-density lipoprotein-cholesterol levels <100 mg/dl on admission (OR 0.67, p < 0.001) and a history of heart failure prior to the index hospitalization (OR 0.54, p = 0.0018). The 30-day compliance with the HDPS regimen was 98%.
  
  
  CONCLUSIONS
  The findings show increased use of HDPS therapy in acute coronary syndrome (ACS) patients, although this mode of medical therapy is still underutilized in the important subset of high-risk ACS patients.
authors.affiliation: Department of Medicine, Beilinson Hospital, Rabin Medical Center, Petach Tikva, Israel.
authors.forename: Avishay
authors.initials: A
authors.lastname: Elis
authors.forename: David
authors.initials: D
authors.lastname: Pereg
authors.forename: Dror
authors.initials: D
authors.lastname: Dicker
authors.forename: Natalie
authors.initials: N
authors.lastname: Gevrielov-Yusim
authors.forename: Ilan
authors.initials: I
authors.lastname: Goldenberg
authors.forename: Shlomi
authors.initials: S
authors.lastname: Matetzky
authors.forename: Eran
authors.initials: E
authors.lastname: Kopel
authors.forename: Robert
authors.initials: R
authors.lastname: Klempfner
mesh_terms: D000704:Analysis of Variance; D000789:Angina, Unstable / Q000188:drug therapy*; D000069059:Atorvastatin; D015331:Cohort Studies; D011307:Drug Prescriptions / Q000706:statistics & numerical data; D005260:Female; D005464:Fluorobenzenes / Q000008:administration & dosage*; D006538:Heptanoic Acids / Q000008:administration & dosage*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D007557:Israel; D008297:Male; D055118:Medication Adherence; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy*; D010351:Patient Discharge; D011743:Pyrimidines / Q000008:administration & dosage*; D011758:Pyrroles / Q000008:administration & dosage*; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D005464:Fluorobenzenes; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D011758:Pyrroles; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium; D000069059:Atorvastatin